cositecan: Clinical Trials

8 trials of cositecan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Terminated 1
Phase 13Completed 2, Terminated 1
Phase 31Completed 1

Follow cositecan: new trials by email Literature Review of cositecan trials Research Report on cositecan

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
Karenitecin, Topotecan - Ovarian Cancer
Phase 3CompletedBioNumerik Pharmaceuticals, Inc.5092007-08-012020-03-12
Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma
Karenitecin, Valproic Acid - Malignant Melanoma
Phase 1 / Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute422005-03-012013-11-25
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
Karenitecin (BNP1350) - Carcinoma, Carcinoma, Non-Small-Cell Lung
Phase 1CompletedBioNumerik Pharmaceuticals, Inc.322004-05-012020-03-12
Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Cositecan, Pharmacological Study - Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Phase 2CompletedGynecologic Oncology Group272003-01-012017-07-13
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
Karenitecin (BNP1350) - Melanoma, Neoplasm
Phase 2CompletedBioNumerik Pharmaceuticals, Inc.462002-05-012020-03-12
Karenitecin in Treating Patients With Recurrent Malignant Glioma
karenitecin - Brain and Central Nervous System Tumors
Phase 1CompletedNational Cancer Institute (NCI)2002-01-012008-07-24
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
Karenitecin (BNP1350) - Brain Neoplasms, Malignant Neoplasms, Brain
Phase 2CompletedBioNumerik Pharmaceuticals, Inc.402001-10-012020-03-12
Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
karenitecin - Lung Cancer
Phase 2CompletedAlliance for Clinical Trials in Oncology552001-04-012016-07-19

Conditions studied

Brain Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Melanoma (2)  ·  Neoplasms (2)  ·  Ovarian Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Astrocytoma (1)  ·  Carcinoma (1)  ·  Central Nervous System Neoplasms (1)  ·  Glioblastoma (1)  ·  Gliosarcoma (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Oligodendroglioma (1)

Sponsors

BioNumerik Pharmaceuticals, Inc. (4)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Gynecologic Oncology Group (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  National Cancer Institute (NCI) (1)

Countries

United States (7)  ·  Hungary (1)  ·  Lithuania (1)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)

Top investigators

Adil Daud, M.D. (1)  ·  Antonius A. Miller, MD (1)  ·  John Kavanagh (1)  ·  Stuart A. Grossman, MD (1)

Results publications

PMID 15893009

NIH funding

U10CA027469 (1), U10CA031946 (1)